business
Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone
Key takeaways
- Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone Jeff Lewis Thu, May 7, 2026 at 8:12 PM GMT+7 2 min read LLY ^GSPC Eli Lilly and Company (NYSE:LLY) is one of the
- 10 Strong Buy S&P 500 Stocks to Invest In.
- On May 1, 2026, Morgan Stanley raised its price target on Eli Lilly to $1,344 from $1,327 with an Overweight rating, citing Q1 results and higher 2026 guidance supporting its GLP-1 outlook.
Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone Jeff Lewis Thu, May 7, 2026 at 8:12 PM GMT+7 2 min read LLY ^GSPC Eli Lilly and Company (NYSE:LLY) is one of the
10 Strong Buy S&P 500 Stocks to Invest In.
On May 4, 2026, Wolfe Research said the FDA received a report on April 30 through its Adverse Event Reporting System involving a case of serious hepatic failure in a patient treated with Eli Lilly and Company (NYSE:LLY)’s Foundayo. After contacting the company, Wolfe Research cited Lilly’s response that it “determined it was not reasonably related to Foundayo,” and said the market reaction appears “overdone,” maintaining an Outperform rating and $1,325 price target.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop